我院自1994年3月～1997年6月对100例急性心肌梗塞(AMI)病人应用国产尿激酶(UK)和德国链激酶(SK)静脉溶栓治疗,以冠状动脉造影结果评价其疗效及安全性.结果发现UK和SK血管再通率分别为60.8%及63%,5周死亡率分别为8.6%及7.4%,严重出血并发症1.85%及2.17%,差别无统计学意义.加大UK剂量至200万U,并不增加血管再通率反而增加出血并发症.临床观察证明UK和SK用于静脉溶栓治疗AMI是安全有效的.特别是UK副作用小,血管再通率高,价格低廉,宜在国内推广使用. In our hospital from March 1994 to June 1997 in 100 cases of acute myocardial infarction (AMI) patients with domestic urokinase (UK) and the German streptokinase (SK) intravenous thrombolytic therapy, coronary angiography to evaluate its efficacy and Safety.Results It was found that UK and SK recanalization rates were 60.8% and 63%, 5-week mortality rates were 8.6% and 7.4%, severe bleeding complications 1.85% and 2.17%, the difference was not statistically significant. UK dose to 2 million U, does not increase the recanalization rate but increased bleeding complications.Clinical observations show that UK and SK for intravenous thrombolytic therapy of AMI is safe and effective .Especially the UK side effects, high rate of recanalization, Low prices, should be promoted in the country.